Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK’s MAGRIT trial fails to meet first co-primary endpoint
The results showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend disease-free survival (DFS) when compared to placebo
The results showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend disease-free survival (DFS) when compared to placebo
In January 2014, the company filed its NDA with the FDA for the treatment of malignant hyperthermia, a condition that can be triggered when genetically susceptible individuals come
TPI 287 is a new taxoid derivative, called as an abeotaxane, which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol
In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for
In March 2009, AVEO and Biogen Idec have entered into an exclusive option and license agreement regarding the development and commercialization of AVEO’s discovery-stage ErbB3-targeted antibodies for the
The oral Impavido has been approved for the three main types of leishmaniasis, including visceral leishmaniasis, cutaneous leishmaniasis and mucosal leishmaniasis. The drug is intended for patients 12
As part of the deal, Eisai will work with LSTM and UoL to discover and develop new drug candidates that efficiently eliminate the bacteria Wolbachia. LSTM is a
The deal will allow Sanofi Pasteur to access the global PCV market of $4bn and the use of PCVs in all countries is recommended by the World Health
Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. As part of the deal, Noven will grant Actavis a non-exclusive, royalty-bearing license to
Andexanet alfa, which secured breakthrough therapy designation from the US FDA, is being developed as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated